long intergenic non-protein coding RNA 1657Genealiases: []
Q-omics provides the consensus-scored LINC01657 profile across patient tissues and cancer cell-line models. LINC01657 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in CHOL. Among the 18 cancer types available for tumor–normal comparison, LINC01657 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, LINC01657 RNA expression shows 5,596 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight CHOL, and STAD as cancer lineages where LINC01657 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01657 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01657 survival associations across molecular data types. LINC01657 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01657 RNA expression–survival associations across cancer types. High LINC01657 expression shows unfavorable associations in CHOL, ACC, KICH, LIHC and BLCA, but favorable associations in PAAD. The CHOL Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CHOL as the clearest survival context for LINC01657 RNA expression.
This table summarizes LINC01657 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01657. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01657 shows lower tumor expression in STAD and higher tumor expression in LUSC. The STAD box plot shows higher LINC01657 RNA expression in normal versus tumor tissue (log2 FC = −0.055, t-test p = .008).
This table shows molecular features associated with LINC01657 in patient tissues and cancer cell lines. In patient samples, LINC01657 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
